Goldman Sachs analyst Salveen Richter maintains $Intellia Therapeutics (NTLA.US)$ with a hold rating, and adjusts the target price from $31 to $20.
According to TipRanks data, the analyst has a success rate of 45.6% and a total average return of 12.7% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Intellia Therapeutics (NTLA.US)$'s main analysts recently are as follows:
After Intellia Therapeutics revealed comprehensive data from its Phase 2 trial of NTLA-2002 against a placebo in hereditary angioedema (HAE), concerns were raised about the market acceptance of gene editing as a potential one-and-done solution due to its irreversible nature and the current uncertainty surrounding long-term safety implications. Additionally, there are questions regarding whether NTLA-2002's effectiveness is substantial when compared to existing treatments.
The latest data from Phase 2 concerning NTLA-2002 indicated an attack reduction which, while in the same ballpark as Phase 3 results from competitors, appeared less robust compared to earlier Phase 1 outcomes presented at EAACI in June. Despite this, the unique advantage of NTLA-2002's potentially single administration, as opposed to the frequent dosing required by competitors, is still seen as a key differentiator. The market potential for NTLA-2002 remains strong, although projections for its peak market share have been adjusted downward along with a more cautious perspective on the chances of success for NTLA-2001 in ATTR, suggesting a need for further validation of the platform.
Analysts have reduced their expectations for Intellia Therapeutics after a Phase 2 study of NTLA-2002 in patients with hereditary angioedema (HAE), expressing a more cautious stance.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
